Patients’ characteristics per CXCR4 mutational status
| Characteristic . | Patient population (N = 26) . | CXCR4 mutated (n = 15) . | CXCR4 wild type (n = 11) . | P . |
|---|---|---|---|---|
| Age at treatment initiation, median (range), y | 65 (46-82) | 65 (46-77) | 68 (54-82) | .46 |
| Age at treatment initiation >65 y, n (%) | 12 (46) | 6 (40) | 6 (55) | .69 |
| Hemoglobin level, median (range), g/dL | 10.2 (6.9-13.2) | 10.6 (6.9-11.6) | 9.8 (7.7-12) | .69 |
| Hemoglobin level ≤11.5 g/dL, n (%) | 21 (81) | 11 (73) | 10 (91) | .35 |
| Platelet count, median (range), × 103/μL | 211.5 (77-420) | 160 (77-346) | 243 (82-420) | .23 |
| Platelet count ≤100 × 103/μL, n (%) | 4 (15) | 3 (20) | 1 (9) | .61 |
| Serum β2-microglobulin level, median (range), mg/L | 3.95 (1.8-10.8) | 3.7 (2-4.8) | 5.3 (1.8-10.8) | .23 |
| Serum β2-microglobulin level >3 mg/L, n (%) | 20 (77) | 10 (67) | 10 (91) | .20 |
| Serum IgM level, median (range), mg/dL | 5074.5 (653-7650) | 5586 (1310-7650) | 4,040 (653-7350) | .005 |
| Serum IgM level ≥7000 mg/dL, n (%) | 2 (8) | 1 (7) | 1 (9) | 1.00 |
| Percentage of bone marrow involvement, median (range) | 55 (5-95) | 55 (5-95) | 52.5 (20-90) | .60 |
| Bone marrow involvement ≥60%, n (%) | 10 (38) | 6 (40) | 4 (36) | 1.00 |
| Lymphadenopathy ≥1.5 cm, n (%) | 14 (54) | 5 (33) | 8 (82) | .02 |
| Splenomegaly ≥15 cm, n (%) | 3 (12) | 1 (6) | 2 (18) | .56 |
| IPSSWM, n (%) | ||||
| Low risk | 5 (19) | 4 (27) | 1 (9) | .38 |
| Intermediate risk | 11 (42) | 6 (40) | 3 (27) | |
| High risk | 10 (38) | 5 (33) | 7 (64) |
| Characteristic . | Patient population (N = 26) . | CXCR4 mutated (n = 15) . | CXCR4 wild type (n = 11) . | P . |
|---|---|---|---|---|
| Age at treatment initiation, median (range), y | 65 (46-82) | 65 (46-77) | 68 (54-82) | .46 |
| Age at treatment initiation >65 y, n (%) | 12 (46) | 6 (40) | 6 (55) | .69 |
| Hemoglobin level, median (range), g/dL | 10.2 (6.9-13.2) | 10.6 (6.9-11.6) | 9.8 (7.7-12) | .69 |
| Hemoglobin level ≤11.5 g/dL, n (%) | 21 (81) | 11 (73) | 10 (91) | .35 |
| Platelet count, median (range), × 103/μL | 211.5 (77-420) | 160 (77-346) | 243 (82-420) | .23 |
| Platelet count ≤100 × 103/μL, n (%) | 4 (15) | 3 (20) | 1 (9) | .61 |
| Serum β2-microglobulin level, median (range), mg/L | 3.95 (1.8-10.8) | 3.7 (2-4.8) | 5.3 (1.8-10.8) | .23 |
| Serum β2-microglobulin level >3 mg/L, n (%) | 20 (77) | 10 (67) | 10 (91) | .20 |
| Serum IgM level, median (range), mg/dL | 5074.5 (653-7650) | 5586 (1310-7650) | 4,040 (653-7350) | .005 |
| Serum IgM level ≥7000 mg/dL, n (%) | 2 (8) | 1 (7) | 1 (9) | 1.00 |
| Percentage of bone marrow involvement, median (range) | 55 (5-95) | 55 (5-95) | 52.5 (20-90) | .60 |
| Bone marrow involvement ≥60%, n (%) | 10 (38) | 6 (40) | 4 (36) | 1.00 |
| Lymphadenopathy ≥1.5 cm, n (%) | 14 (54) | 5 (33) | 8 (82) | .02 |
| Splenomegaly ≥15 cm, n (%) | 3 (12) | 1 (6) | 2 (18) | .56 |
| IPSSWM, n (%) | ||||
| Low risk | 5 (19) | 4 (27) | 1 (9) | .38 |
| Intermediate risk | 11 (42) | 6 (40) | 3 (27) | |
| High risk | 10 (38) | 5 (33) | 7 (64) |
IPSSWM, International Prognostic Scoring System for Waldenström Macroglobulinemia.